BioCentury
ARTICLE | Clinical News

Aprea reports Phase Ib/II response data for APR-246 in MDS

April 27, 2018 7:49 PM UTC

Aprea Therapeutics AB (Stockholm, Sweden) said APR-246 plus Vidaza azacitidine led to an overall response rate (ORR) of 100%, including six complete responses and two marrow complete responses, in eight evaluable patients with myelodysplastic syndrome (MDS) in a Phase Ib/II trial. Median progression-free survival (PFS) and overall survival (OS) have not yet been reached, and no responding patient has experienced relapse. The maximum tolerated dose (MTD) has also not yet been reached. Data were presented at the American Association for Cancer Research meeting in Chicago. The H. Lee Moffitt Cancer Center and Research Institute sponsored the trial...